Palvella Therapeutics, Inc (PVLA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $150.56 (-2.44%), Market cap $1.63B, 52-week low–high $20.51 ~ $148.34.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Financial statements, price targets, institutional (13F) holdings and related news for Palvella Therapeutics, Inc are updated in real time on BlackAll Trade.
Palvella Therapeutics, Inc trades at $150.56 (-2.44%). Real-time quotes and charts are available on BlackAll Trade.
Palvella Therapeutics, Inc has a market cap of about $1.63B.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company